Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study
Authors:
- R. ChopraRCR. Chopra
- J. D. EatonJEJ. D. Eaton
- A. GrassiAGA. Grassi
- M. PotterMPM. Potter
- B. ShawBSB. Shaw
- C. SalatCSC. Salat
- P. NeumeisterPNP. Neumeister
- G. FinazziGFG. Finazzi
- M. IacobelliMIM. Iacobelli
- K. BowyerKBK. Bowyer
- H. G. PrenticeHPH. G. Prentice
- T. BarbuiTBT. Barbui
- 1 December 2000
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 111 (4) , 1122-1129
Abstract
Severe hepatic veno-occlusive disease (VOD) is a recognized complication of autologous and allogeneic stem cell transplantation (SCT) that is often fatal. Defibrotide (DF) is a polydeoxyribonucleotide that has been found to have anti-thrombotic, anti-ischaemic and thrombolytic properties without causing significant anticoagulation. Preliminary studies have demonstrated activity for DF in the treatment of VOD, with minimal associated toxicity. In the present study, 40 patients who fulfilled established criteria for VOD were treated with DF on compassionate grounds in 19 European centres; 28 patients met risk criteria predicting progression of VOD and fatality or had evidence of multiorgan failure (MOF), and were defined as 'poor-risk'. DF was commenced intravenously at a median of 14 d (range, -2 d to 53 d) post SCT at doses ranging from 10 to 40 mg/kg. The median duration of therapy was 18 d (range, 2--71 d). Twenty-two patients showed a complete response (CR) (bilirubin < 34.2 micromol/l and resolution of signs/symptoms of VOD and end-organ dysfunction) [CR = 55%, confidence interval (CI) 40--70%] and 17 patients (43%) are alive beyond d +100. Ten poor-risk patients showed a complete response (CR = 36%, CI 21--51%). These results demonstrate that DF is an active treatment for VOD following SCT and a randomized trial is now underway in order to further evaluate its role.Keywords
This publication has 15 references indexed in Scilit:
- Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantationBone Marrow Transplantation, 1999
- Defibrotide versus Placebo in the Treatment of Intermittent ClaudicationClinical Drug Investigation, 1994
- Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.Journal of Clinical Oncology, 1993
- Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonistEuropean Journal of Pharmacology, 1993
- Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 PatientsAnnals of Internal Medicine, 1993
- DefibrotideDrugs, 1993
- Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantationBlood, 1992
- Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markersThrombosis Research, 1991
- VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATIONTransplantation, 1987
- Effect of a New Antithrombotic Agent (Defibrotide) in Acute Renal Failure Due to Thrombotic MicroangiopathyNephron, 1985